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introduced into cancer cells, in which the gene is inactivated, to restore 
the cell’s normal gene functions. Such introduction of TSGs in the 
cancer cells generally induces apoptosis and/or cell cycle arrest. Gene 
therapy using various known and newly identiﬁed TSGs as therapeutic 
genes have reached clinical trials for treatment of several cancer types. 
However, as different types of cancers have different tumor suppressor 
deﬁciencies, the strategy must be customized to each type. Thus, the 
aim of this study is to identify and characterize novel TSG candidate(s) 
speciﬁc SCLC, which eventually can be tested for use in cancer gene 
therapy. 
By a global gene expression analysis (Affymetrix) on a large panel 
of SCLC cell lines, corresponding tumor xenografts, and transformed 
mouse cell lines, we have identiﬁed four genes, whose expression is 
markedly downregulated in cancer and transformed mouse cell lines 
compared to normal cells and tissues. This was further veriﬁed by 
semi-quantitative RT-PCR. To determine whether they posses tumor 
suppressing activity we are currently investigating the effect of overex-
pression of each of these genes on cell proliferation, migration and cell 
cycle arrest by transiently transfecting selected SCLC and transformed 
mouse cell lines. If any demonstrate tumor suppressive activity, they 
will be chosen as potential candidates for the development of gene 
therapy for patients with SCLC.
An update will be presented.
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Background: STI571 Gleevec, Imatinib(c) is the ﬁrst cancer -related 
signal transduction inhibitor which selectively suppresses the activity 
of c-KIT, ABL and platelet-derived growth factor receptor(PDGFR). 
Methods: We conducted MTT assay to explore the growth inhibitory 
effect of STI571 alone or with cisplatin on lung cancer cells, cell cycle 
analysis to conﬁrm the cell distribution, immunocytochemistry to test 
the expression of PDGFRs, c-KIT in the non-small cell lung cancer cell 
lines immunohistochemistry to investigate the expression of PDGFRs 
and c-KIT. 
Results: A549-resistant cell lines showed marked inhibition of cell 
growth after treatment with STI571 and combination with cisplatin,but 
not A549-sensetive cells. Cell cycle analysised by ﬂow cytometry 
revealed that STI571 treatment increased the fraction of A549-resistant 
cells in S and G2/M phases,respectively,indicating induction of S and 
G2/M transition arrest.A549 cell lines highly express PDGFRs, A549-
resistant cell lines also express c-KIT.
Conclusion: These results provide a potential therapeutic selection for 
non-small cell lung cancer. STI571 as a single agent or in combination 
with cisplatin is a potential new targeted strategy.
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Background and Objectives: Most lung cancer patients cannot be 
cured with current therapeutic modalities. Drug resistance is one of 
the major causes in treatment failure of non-small cell lung cancer 
{NSCLC). Classical drug resistant mechanisms have been elucidated 
upon monocellular models. However, these models do not consider the 
tumor microenvironment in vivo. Recently, interactions between the tu-
mor cells and extracellular matrix (ECM) have been shown to be one of 
the mechanisms of drug resistance. We investigated effects of ECM on 
cisplatin-induced apoptosis of the cell line A549 and cisplatin-resistant 
cell line A549-DDP, and the role of phosphatidylinositol 3’-kinase(PI3-
K) in ECM’s signal pathway. 
Methods: A549 and A549-DDP cells were cultured in RPMI 1640 
supplemented with 10% fetal calf serum in vitro, 6 µmol/L cisplatin 
(DDP )was added to maintain the drug resistant phenotype of the A549-
DDPcells. The inhibitory effects of DDP and/or LY294002 (PI3-K 
inhibitor) on cellular proliferation were tested by methabenzthiazuron 
(MTT) assay. Immunocytochemistry was used to detect the expression 
of extracellular matrix and integrin β1 of these two cell lines, respec-
tively. Cell adhesion experiments were used to test cell adhesion rates. 
Flow cytometry was applied to study the inﬂuence of collegen IV (C 
IV) and LY294002 on A549/DDP cells’ apoptosis and cell cycle distri-
bution before and after DDP treatment. 
Results: The expression of ECM proteins in cisplatin-sensitive and cis-
platin-resistance lung cancer cells were different. Extracellular matrix 
Cmediated cell adhesion promotes survival of A549 and A549-DDP 
cells from cisplatin insults. Pre-coating with collagen IV protect non-
small cell lung cancer cells from drug-induced growth inhibition, which 
is PI 3-kinase/Akt-dependent. Combining cisplatin with LY294002 
caused greater increases in apoptosis compared with that caused by the 
inhibitor or cisplatin alone. Collagen IV changed A549 cells cell cycle 
distribution, with an increase in G1 phase, a reduction in S and G2/M 
phases, as treated with cisplatin or combined with LY294002. After be-
ing infected with dominant-negative forms of integrin β1 plasmid, both 
of these two cell lines can become relatively sensitive to cisplatin. 
Conclusions: ECM may provide protection against cisplatin-induced 
apoptosis of A549 and A549-DDP cells, while LY294002 increases 
the growth inhibitory effect of cisplatin. Integrin &β1 signaling and 
PI3-Kinase pathway may be important survival pathways of drug-in-
duced apoptosis in lung cancer cells and activation of this pathway may 
contribute to the generation of drug resistance.
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Dual-agent chemotherapy is the current standard of care for patients 
with advanced non-small-cell lung cancer (NSCLC). While progress in 
patients’ outcome has been made, signiﬁcant variability in the efﬁcacy 
and toxicity of anticancer drugs is observed in unselected popula-
tions of patients. Recent studies have shown promise for improved 
outcome if therapy is selected based on molecular tumor character-
istics. Although resistance to gemcitabine and/or platinum are likely 
multifactorial, nucleotide metabolism and DNA repair have emerged 
as critical components. Previous studies have demonstrated a relation-
ship between RRM1 gene expression and differential sensitivity to 
gemcitabine/cisplatin. RRM1 is involved nucleotide metabolism and 
the nucleotide excision repair pathway, and up-regulation of this gene 
results in resistance to these agents.
Methods: We have generated three human cancer cell lines derived 
from lung, colon, and breast, with increased and decreased RRM1 
expression by stable transfection. The authenticity of cell lines was 
veriﬁed by genome typing. Chemosensitivity testing of different drugs 
was performed in vitro with the CellTiter-Glo® Luminescent cell vi-
ability assay.
Results: RRM1 expression at the mRNA and protein level was vari-
able among clones. For drug testing, clones with a greater than 2-fold 
increase (for up regulation) and a greater than 50% decrease (for down 
regulation) of RRM1 expression at the mRNA and protein level were 
selected. Scrambled sequence and out of frame RRM1 constructs were 
used to generate the control clones. When examining the associa-
tion between the expression of RRM1 and the IC50 of drugs, RRM1 
overexpressing clones showed resistance and underexpressing clones 
sensitivity to some drugs; most notably to gemcitabine.
Conclusions: Understanding the role of speciﬁc genes on DNA dam-
age repair and response to treatment is paramount to the evolving con-
cept of individualized chemotherapy. It is well known the efﬁcacy of 
various treatment regimens varies greatly among patients. Our in vitro 
RRM1 regulation model has the potential to not only help with tailor-
ing the clinical selection of chemotherapy but also with understanding 
the function of RRM1 in tumor biology.
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Background: Dendritic cells (DCs) are the most potent antigen-pre-
senting cells for initiating cellular immune response. Cancer-testis 
antigens (CTA) are the biggest tumor antigens family expressing only 
in some tumors and genital system but not in normal cells. XAGE-
1b gene is one of CTA which highly expresses in lung cancer and 
has strong immunogenicity. Our study was to examine whether DCs 
loaded with XAGE-1b protein could induce speciﬁc antitumor response 
against lung cancer cells in vitro. 
Methods: Tumor tissues and normal lung tissues were obtained by 
operation from 30 non-small cell lung cancer patients. Cancer cells 
and normal lung epithelium cells were cultured and saved as target 
cells. Total RNA were isolated and RT-PCR was done to determine 
XAGE-1b gene expression. XAGE-1b gene was cloned by constructing 
expression vector and recombinant protein was expressed and puri-
ﬁed by using BL21 (DE3) E. coli and AKTA-FPLC. Peripheral blood 
monocytes were isolated from 20ml blood and cultured to be DCs in 
serum-free DCs Medium. DCs were loaded with XAGE-1b protein 
through coculture and induced T lymphocytes into XAGE-1b-speciﬁc 
cytotoxic T lymphocytes (CTLs). The cytotoxicity of CTLs was then 
measured by cytotoxic assay. 
Results: 12/30(40%) lung cancer tissues expressed XAGE-1b gene, 
most of which were adenocarcinoma (11/12, 91.7%). None of normal 
tissues expressed it. Gene sequencing and western blot conﬁrmed the 
expression vector construction and recombinant protein expression. Im-
munoﬂuorescence identiﬁcation showed the accumulation of XAGE-1b 
protein in immature DCs. T lymphocytes were stimulated twice with 
XAGE-1b protein-loaded DCs. Cytotoxic assay showed that the CTL 
cytotoxicity was much stronger for XAGE-1b positive tumor cells than 
for XAGE-1b negative tumor cells and it was almost none for normal 
lung epithelium cells. 
Conclusions: Our study indicates that DCs loaded with XAGE-1b 
protein could induce speciﬁc antitumor effect against lung cancer cells 
in vitro and this model offers a new approach to the immunotherapy for 
lung cancer.
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Introduction: Lung cancer is a common malignancy worldwide with 
high morbidity and mortality. With increasing incidence of lung cancer 
world wide, there are few studies in Nigeria which have looked at the 
clinical and histological patterns of lung cancer in out center hence this 
study.
Method: We conducted a retrospective review of all cases of lung 
cancer seen at the National Hospital, Abuja, Nigeria over a 6 year 
period from 2001-2006. Cases were identiﬁed from the admission and 
discharge ﬁles on the wards and searched from the main record library 
.All cases which were retrieved were presented. Data were expressed 
using descriptive statiatics.
Results: Thirty two cases of Lung cancer were identiﬁed out of which 
sixteen cases were fully retrievable. These are presented in this study. 
The male to female ratio is 1.7:1 with a mean age of 55years (range 
from 40-85years). Smoking was the commonly identiﬁed risk factor 
which was present in 50% of the cases (7 males and 1 female).
Other identiﬁable potential risk factors were indoor and out door pol-
lution from burning biomass (18.7%), exposure to asbestos (12.5%). 
In 18.2% no risk factor could be identiﬁed.75% have a primary lung 
cancer of which adeno carcinoma was the commonest while secondar-
ies from breast, bone and cervical cancer was seen in the remaining 
25%. At presentation, 85% of the patients have developed extensive 
disease three patients with secondary lung cancer received combination 
chemotherapy and while radiotherapy with high dose steroid was given 
in those with SVO.
